
First Smallpox Treatment Tops SPT Week in Review
Top news of the week from Specialty Pharmacy Times.
5. FDA Announces Voluntary Recall of Medicines Containing Valsartan Due to Impurity Detection
Officials with the US FDA are alerting health care professionals and patients of a voluntary recall of several, but not all, drug products containing the active ingredient valsartan.
4. Specialty Drug Coverage Varies Widely Among Largest US Commercial Insurers
Study finds that specialty drug coverage policies are mostly inconsistent across health plans and many treatments have multiple restrictions to access.
3. Novel Therapeutic Approach Using Protein Supplementation Could Delay ALS Symptoms
Supplementation of the protein in the nerve cells prevented nerve degeneration, muscle atrophy, and paralysis in an amyloid lateral sclerosis mouse model.
2. FDA OKs First Darunavir-Based Single-Tablet Treatment Regimen for HIV
Symtuza (darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg, and tenofovir alafenamide 10 mg) offers a new treatment option to adults living with HIV.
1. FDA Approves First Smallpox Treatment to Counter Bioterrorism
Tecovirimat (TPOXX, SIGA) is the first drug with an indication for the treatment of smallpox.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.